Simile has now done the sort of financing sequence that makes lesser cap tables sit up straighter. Five months after emerging from stealth with a $100 million Series A led by Index Ventures, the synthetic-user startup says it has closed a $200 million Series B at a $2 billion valuation, with Greenoaks leading and Index, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventures back for more.

That is not just momentum. That is a market deciding it would like to prepay for the category.

Simile's pitch is simulated users for marketing and product research, which sounds either visionary or like focus groups got rewritten by someone with a GPU budget. Founder Joon Sung Park comes with a Stanford pedigree and the Smallville research project, where AI agents carried on remarkably human little lives. Investors are betting that work can be turned into an enterprise product before the phrase synthetic user starts sounding like a compliance memo.

The subtext is the part worth your time, darling reader. A $2 billion valuation this quickly means buyers and backers alike are willing to believe there is real budget behind replacing some human research loops with modeled behavior. It also means everyone funding adjacent AI tooling now has a fresh comp to wave around in partner meetings. If you squint, Simile is not being priced like a quirky research offshoot. It is being priced like a future tax on product teams that want answers faster than actual humans care to provide them.

Whether the simulated users prove truly predictive is tomorrow's anxiety. Today's fact is simpler: the unicorn factory still loves a company that can dress uncertainty up as infrastructure.